Your enquiry0GH-axis research
RESEARCH USE ONLYCJC-1295 no DAC + Ipamorelin
This peptide blend combines CJC-1295 without DAC and Ipamorelin, with a total labelled amount of 20 mg per vial. Select your format and quantity for pricing, batch availability and lead time.
Minimum listed format shown. Refer to the selected SKU specifications; final packaging is confirmed with your quotation.
Active raw material procurement specification before formulation. Finished-product content and batch testing are separate attributes.
Price, batch and delivery terms confirmed with your quotation.
ABOUT THE MATERIAL
Identity, scientific context and the details that distinguish this entry.
This peptide blend combines CJC-1295 without DAC and Ipamorelin, with a total labelled amount of 20 mg per vial.[Sources]
The CJC component is the tetrasubstituted 29-residue GRF analogue without DAC. Ipamorelin is the pentapeptide H-Aib-His-D-2-Nal-D-Phe-Lys-NH₂. These components connect GHRH- and secretagogue-receptor research.
Component-resolved identification, assay and stability measurements characterize a blend alongside its total labelled amount.
A CLOSER LOOK
Read each finding with its study model and material identity.
The named components are CJC-1295 without DAC and Ipamorelin. Chromatographic separation and component-specific identification support measurement of each ingredient. Compatibility and stability testing uses the complete mixture as the test material.
Systematic substitution studies on GHRH(1–29) analogues measured pituitary GH release as a function of peptide sequence. This provides pathway background for the GHRH-related component; it does not evaluate this complete blend or DAC conjugation.
PRODUCT DATA
Product specifications and batch results are confirmed with your quotation and COA.
Review available records or add your document request to the enquiry.
BATCH DOCUMENTATION
Add requirements to your enquiry. The team will confirm availability and scope for the offered lot.
Match the offered lot number, identity, test methods and reported results.
Ask for available chromatograms and mass-identity records, including the method and reporting scope.
Confirm handling, transport and storage information for the offered material and packaging.
A document request adds no purchase quantity. Have a batch reference? Open batch records ↗
BEFORE YOU ENQUIRE
Component-resolved identification, assay and stability measurements characterize a blend alongside its total labelled amount.
Use the specification and available safety or stability information for the offered lot, form and packaging. Request written conditions before ordering; literature alone does not establish a universal temperature, shelf life or reconstitution procedure.
The displayed value is a catalogue specification. Assess the offered lot against its matching COA and method. Chromatographic purity, component content and biological activity are different measurements; confirm which results are available.
Include the exact SKU, quantity in boxes, destination, desired timing and document requirements. State any label or packaging needs. Pricing, availability, lead time and document scope are confirmed in the quotation.
SOURCES
Content updated
Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. 1998, DOI: 10.1530/eje.0.1390552
Receptor pharmacology and animal endocrine assays
Cervini LA, Donaldson CJ, Koerber SC, Vale WW, Rivier JE. 1998, DOI: 10.1021/jm970618s
GHRH(1–29) analogue structure–activity assays
Publications describe their own study materials and methods. They are distinct from BatchTide specifications and lot-release records. Materials listed here are for laboratory research only, not for human or veterinary use.
EXPLORE THE CATALOGUE
Explore related entries. Similar research contexts do not establish interchangeability.